Readings Newsletter
Become a Readings Member to make your shopping experience even easier.
Sign in or sign up for free!
You’re not far away from qualifying for FREE standard shipping within Australia
You’ve qualified for FREE standard shipping within Australia
The cart is loading…
Emerging Paradigms in Delivery of Therapeutic Agents for the Treatment of Glioblastoma describes the intense research and clinical developments that are required to optimize the available treatment options and the potential side effects to heal brain cancer. The success of this strategy includes the use of validated biomarkers, appropriate patient selection criteria, strategies to prevent adverse events, and the implementation of immunotherapy in multimodal treatment approach. In 18 chapters, this title sets forth the rationales for promising therapies like immunotherapy, including immune checkpoint blockade, chimeric antigen receptor T (CAR T) cell therapy, oncolytic virotherapy, and vaccine therapy.
In addition, the book reviews potential novel agents, the current status of preclinical and clinical trials, and the challenges and future perspectives in glioblastoma immuno-oncology. This book is a valuable resource for health professionals, scientists and researchers, health practitioners, students, and all those who wish to broaden their knowledge in the allied field.
$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout
Emerging Paradigms in Delivery of Therapeutic Agents for the Treatment of Glioblastoma describes the intense research and clinical developments that are required to optimize the available treatment options and the potential side effects to heal brain cancer. The success of this strategy includes the use of validated biomarkers, appropriate patient selection criteria, strategies to prevent adverse events, and the implementation of immunotherapy in multimodal treatment approach. In 18 chapters, this title sets forth the rationales for promising therapies like immunotherapy, including immune checkpoint blockade, chimeric antigen receptor T (CAR T) cell therapy, oncolytic virotherapy, and vaccine therapy.
In addition, the book reviews potential novel agents, the current status of preclinical and clinical trials, and the challenges and future perspectives in glioblastoma immuno-oncology. This book is a valuable resource for health professionals, scientists and researchers, health practitioners, students, and all those who wish to broaden their knowledge in the allied field.